Results of randomized phase II #PDAC trial that will be a benchmark for future trials. Patients receiving 2nd-line gemcitabine/nab-paclitaxel alone after FOLFIRINOX had median OS of 6.6 months, the median PFS was 2.7 months, and the ORR was 2.9%. ⬇️⬇️⬇️ https://t.co/ofadE7aRQu

PASS-01:ph II mFFX v GnP;#PDAC denovo met ds; excl gBRCA/PALB2 ➡️no clinically sig diff GnP v mFFX ➡️basal-like poor OS-mPFS on mFFX 3 mths ➡️54% receive 2nd line; mOS<6mths ➡️PDOs/ctDNA to come @AmberHabowski 1st-line biomarkers essential-RAS &🤞subtype https://t.co/bZ1TCzTYiK

Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer. Read the full article. https://t.co/O2agTcJMQs #pamcsm

Please join us in congratulating Alice Shaw, MD, PhD, on being named our next Chair of the Department of Medical Oncology. As Chair of the Department of Medical Oncology, Shaw will oversee more than 300 faculty and more than 80 cancer research laboratories, and will drive the

Final COMPASS trial data advanced #PDAC ➡️268 WGS& 253RNA-seq ➡️basal-like& hi GRIm-S ⬇️OS, both unique TME inc CD8 variation,NB primaries vs mets ➡️LTS :HRD, KRAS WT ➡️KRAS major enriches basal, >type II DM ➡️LAPC≠intact SMAD4 ➡️47% receive 2nd line tx https://t.co/wXcQY1kPvR

Excellent work by @DanaFarber colleague @asaf_maoz presenting his #ASCO25 oral abstract: Sensitivity of age and family history (FH) criteria for determining pancreatic cancer (PC) surveillance (PCS) eligibility among individuals with hereditary PC risk. https://t.co/cF8lxXiCzy

🔥NeoPancOne🇨🇦 ➡️mFFX in resectable PDAC ➡️exploring GATA6&subtypes ➡️mEFS &OS 16.3 &34.2mths ➡️1yr EFS 90% in GATA6 hi vs 50% lo ➡️1yr OS classical 95% vs.57% basal-like ⭐️Time to subtype upfront in all PDAC recognising plasticity @OncoAlert #ASCO25 @OICR_news @pmcancercentre

No doubt the best GI Onc division on the planet! So grateful to work with brilliant, kind, and visionary colleagues #ASCO25 @DanaFarber @DanaFarberNews @DFarberYoungCRC @ASCO

Immediately practice changing and deserves discussion with each pt! The first RCT supporting structured exercise after adjuvant therapy for colon cancer. It’s striking how exercise improves survival, especially compared to drugs with FDA approval and payer support. 👀 #ASCO25

Presented at #ASCO25: The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer. Full BREAKWATER phase 3 trial results: https://t.co/NNkryRQjCa

Pancreatic cancer cells express cryptic peptides shared across patients that may be therapeutic targets, according to new research in Science. 📄: https://t.co/x9FvFIozZO #SciencePerspective: https://t.co/Ouk1lbbDvI

Congratulations to Will Freed Pastor @DanaFarber_Hale on his foundational @ScienceMagazine paper!! Totally transforms the landscape of #PancreaticCancer tumor antigens. @LabJacks @break_cancer @lustgartenfdn https://t.co/Pzuz5tkRbz

Congratulations to @IamLinghua @GuangshengPei @jiminmin_v and all our exceptional collaborators at @MDAndersonNews & beyond for today's study in @Nature on spatial mapping of transcriptomic plasticity in metastatic #PancreaticCancer The full text link is

One of the best reviews this year on pharmacological targeting of KRAS - direct or indirect - is written by @norbertkraut1 @Sandra_Misale @gerlach_d @MarcoHHofmann in @CD_AACR - #OpenAccess & worth reading! https://t.co/0OXb2L78F3

We are gearing up for the 6th Annual Patient and Family Forum on Saturday, March 29th, with new Beyond CRC hats! It is not too late to register for the event! #ColorectalCancer #CRC #DanaFarber

Pancreatic cancer remains one of the toughest cancers to treat. But newer therapies entering clinical trials are giving doctors hope.

Paper is out!!! FDA approved for NRG1 Fusion+ Non-Small Cell #LungCancer and #PancreaticCancer Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer https://t.co/LCPM14lBaF @AliSchram @StephenVLiu @GIcancerDoc @KReissMD @MerusNV @NEJM @MSKCancerCenter @LombardiCancer

Results from the phase II study of zenocutuzumab in #NRG1 fusion+ cancers now @NEJM. RR 30% with DOR 11.1m, PFS 6.8m, favorable safety profile. These cancers do not respond well to standard therapy. Zeno FDA approved for NSCLC, pancreatic cancer. https://t.co/SEpYGYU1IS

Great data for pts w/ 2+ line met anal cancer for pembrolizumab+ficerafusp alfa (EGFR/TGFb bispecific) -ORR 29% & 41% 12-mo DFS=benefit in liver mets+pCR for exceptional responder ! Exciting signal as combination immuotherapy in anal cancer! @MDAndersonNews #endcancer @BicaraTx

Is 2025 going to be the year Pan-RAS inhibitors make it into the clinic? Pan-RAS inhibitor shows early/deep molecular response (and 36% response rate) for G12X mutated pancreatic cancer. (Significant AEs: rash, diarrhea, nausea, vomiting) https://t.co/34qqj8oqGV

ESOPEC, a large randomized trial involving patients with resectable esophageal cancer, showed that perioperative chemotherapy improved overall survival as compared with preoperative chemoradiotherapy. Full trial results: https://t.co/KcViF0c2aW Editorial: Multimodal Treatment